CIK 0000949858
- Non-accelerated filer
- Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Tickers
- ACHV QUIT
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 954343413
- Phone
- +1 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
Securities
- ACHV Common stock Nasdaq
- QUIT Common Shares Nasdaq
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Scientific Officer acquired 16,971,560 shares (grant or award)
- 4 Grant or award President & CEO acquired 23,335,897 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Shares withheld for taxes President and CEO gave up 4,472 shares (to pay taxes)
- 4 Shares withheld for taxes EVP, CMO gave up 1,633 shares (to pay taxes)
- 4 Shares withheld for taxes EVP, CMO gave up 3,369 shares (to pay taxes)
- 4 Shares withheld for taxes CFO gave up 1,021 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 9,690 shares (to pay taxes)
- 4 Open-market sale CFO sold 1,380 shares at $0.57 ($787)
- 4 Open-market sale EVP, CMO sold 1,437 shares at $1.03 ($1,473)
- 4 Open-market sale President and CEO sold 4,856 shares at $1.03 ($4,979)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 12 of 24 · 465 filings